[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354019-105":59,"doc-detail-354019-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","real-world-treatment-patterns-and-medical-burden-in-patients-with-nsclc-a-retrospective-database-study-in-japan","Real-world treatment patterns and medical burden in patients with NSCLC: a retrospective database study in Japan","","Aim: We investigated treatment patterns and healthcare resource utilization (HRU) to clarify unmet medical needs in second and later lines among Japanese patients with advanced non-small cell lung cancer (NSCLC). Methods: A retrospective claims-database study (Jan 2019–Dec 2024) assessed treatment patterns, time to treatment discontinuation (TTD), and HRU for patients with versus without actionable genomic alteration (AGA) therapy. Results: 22,886 patients were included; short TTD and higher hospitalization/HRU were observed with shorter second-line durations, highlighting heterogeneous care.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/real-world-treatment-patterns-and-medical-burden-in-patients-with-nsclc-a-retrospective-database-study-in-japan/354019/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/real-world-treatment-patterns-and-medical-burden-in-patients-with-nsclc-a-retrospective-database-study-in-japan/354019.png","ImageObject",300,407,{"name":92,"@type":93},"Alex Sinclair","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the study aim regarding NSCLC treatment in Japan?","Question",{"text":113,"@type":114},"The study evaluated real-world treatment patterns and healthcare resource utilization to clarify unmet medical needs in second and later treatment lines for Japanese patients with advanced NSCLC.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How did the researchers compare patients with and without actionable genomic alteration (AGA)?",{"text":118,"@type":114},"Patients were grouped by whether they had actionable genomic alterations for which targeted therapies were available, then treatment patterns, TTD, and HRU were analyzed separately for each group.",{"name":120,"@type":111,"acceptedAnswer":121},"What did the study find about treatment duration and healthcare burden?",{"text":122,"@type":114},"Hospitalization rates and other HRU measures were higher when second-line treatment duration was shorter (\u003C3 months) versus longer (≥3 months), and overall treatment patterns showed short durations with greater challenge in patients without AGA.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},354019,1790149463,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":41,"preview_page_count":19,"preview_urls":146},1099523882182,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","FUTURE ONCOLOGY  \n2026, VOL. 22, NO. 9, 1083–1094  \n[https://doi.org/10.1080/14796694.2026.2645989](https://doi.org/10.1080/14796694.2026.2645989)  \nRESEARCH ARTICLE     \nReal-world treatment patterns and medical burden in patients with NSCLC: a retrospective database study in Japan  \nLinghua Xua, Sona-Sanae Aoyagia, Yusuke Nukuib, Tomoyo Ogurib and Kanae TogoaaAccess & Value, Pfizer Japan Inc., Tokyo, Japan; bOncology Medical Affairs, Pfizer Japan Inc., Tokyo, Japan  \nABSTRACT  \nAim: We investigated treatment patterns and healthcare resource utilization (HRU) to clarify unmet medical needs in second and later lines among Japanese patients with advanced non-small cell lung cancer (NSCLC) .  \nMethods: This retrospective study included patients with NSCLC having first-line treatment from a claims database (January 2019−December 2024). Treatment patterns, time to treatment discontinuation (TTD), and HRU were described for patients with/without actionable genomic alteration (AGA) therapy.  \nResults: Overall, 22,886 patients (with AGA, 7,831; without AGA, 15,055) were included. In patients with AGA, targeted therapy (48.6%), platinum doublet (12.1%), and chemo monotherapy (10.4%) were common second-line treatments, with median TTD 7.5, 4.3, and 3.0 months, respectively. In patients without AGA, chemo monotherapy (45.1%), ICI monotherapy (17.8%), and platinum doublet (13.9%) were the most prescribed second-line treatments with relatively short median TTD (2.7, 3.7, and 3.2 months, respectively) . Hospitalization rates were higher in patients with second-line treatment duration \u003C3 versus ≥3 months (incidence/100 person-years, 67–88 vs 35–38) .  \nConclusion: Treatment patterns were heterogeneous with short durations that were associated with higher rates of HRU. The study findings highlight the challenge of current treatments, and need for effective treatment options in clinical practice in Japan.  \nPLAIN LANGUAGE SUMMARY  \nNSCLC: Real-world treatment patterns in Japan  \nNon-small cell lung cancers (NSCLC) are a common type of lung cancer case in Japan. First-line treatments for NSCLC are well defined. However, second-line and further treatments are varied. We assessed treatment patterns in Japanese patients with advanced NSCLC. We used real-world data from MDV, a large claims database in Japan. We included patients who had first-line treatment for NSCLC (2019–2024) . Patients who had specific gene changes (called actionable genomic alterations [AGA]) for which specific targeted therapies (AGA therapy) are available were grouped together. Thus, patients were divided into two groups: with AGA therapy (n = 7,831) and without AGA (n = 15,055) .  \nIn those with AGA, targeted therapy (48.6%), platinum doublet (12.1%), and chemotherapy using one drug (10.4%) were common second-line treatments. Targeted therapy was continued over longer duration (7.5 months) than other treatments. Also, 17.8% of patients were re-treated with targeted therapy in the second-line. In patients without AGA, many (45.1%) switched to chemotherapy using one drug in the second-line. However, it was continued for a shorter duration (2.7 months) . Further, we observed a higher use of healthcare facilities in patients with shorter treatment durations. Overall, realworld treatment patterns were varied and with short durations in Japanese patients with NSCLC. Patients without AGA experienced greater challenges than those with AGA.  \nThis study highlights the healthcare burden and need for effective treatment options for NSCLC in clinical practice in Japan.  \nARTICLE HISTORY  \nReceived 26 December 2025 Accepted 11 March 2026  \nKEYWORDS  \nClaims database; healthcare resource utilization; nonsmall cell lung cancer; medical burden; real-world data; treatment discontinuation; treatment patterns; unmet medical needs  \n1. Introduction  \nGlobally, lung cancer remains the most common diagnosed cancer and cause of cancer-related mortality, with 2.48 million new cases and 1.8 millio","cbCaicqhjSxw9x0i","https://ap.wps.com/l/cbCaicqhjSxw9x0i","pdf",8853020,12,"English","# Introduction\n# Methods\n# Results\n## Treatment patterns and time to treatment discontinuation\n## Healthcare resource utilization and hospitalization\n# Conclusion\n# Plain language summary","[{\"question\":\"What was the study aim regarding NSCLC treatment in Japan?\",\"answer\":\"The study evaluated real-world treatment patterns and healthcare resource utilization to clarify unmet medical needs in second and later treatment lines for Japanese patients with advanced NSCLC.\"},{\"question\":\"How did the researchers compare patients with and without actionable genomic alteration (AGA)?\",\"answer\":\"Patients were grouped by whether they had actionable genomic alterations for which targeted therapies were available, then treatment patterns, TTD, and HRU were analyzed separately for each group.\"},{\"question\":\"What did the study find about treatment duration and healthcare burden?\",\"answer\":\"Hospitalization rates and other HRU measures were higher when second-line treatment duration was shorter (\\u003c3 months) versus longer (≥3 months), and overall treatment patterns showed short durations with greater challenge in patients without AGA.\"}]","Real-world treatment patterns and medical burden in patients with NSCLC: a retrospective database study in Japan | PDF",1790108484,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a419b10c7abc73c10c38cc77412d70af.webp",983,1280,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a6e9d2b5a92fde21404b3f1dea20425.webp",982,1278,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/540bda51dd767d50a3f3b56e35d5ae6b.webp",981,1277,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5d0edfb306e6fe0a5c2ec7ee526106d7.webp",980,1276]